Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate
Magenta Therapeutics, Inc. (MGTA)
Last magenta therapeutics, inc. earnings: 11/13 08:00 am
Check Earnings Report
Company Research
Source: Business Wire
-- Data in non-human primates from C100 program show potent stem and immune cell depletion with anti-CD45 amanitin ADC that is well tolerated at efficacious doses -- -- C200 development candidate, anti-CD117 amanitin ADC, showed potent and selective stem cell depletion and immune system preservation in non-human primates and was well tolerated -- -- Additional poster highlights preclinical data on anti-leukemia survival benefit with C100 and C200 targeted conditioning programs -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company highlighted preclinical research on its targeted conditioning programs in four presentations and posters at the Transplant and Cellular Therapy (TCT) annual meeting.
Show less
Read more
Impact Snapshot
Event Time:
MGTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTA alerts
High impacting Magenta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MGTA
News
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 priceMarketBeat
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) had its price target lowered by analysts at Mizuho from $17.00 to $8.00.MarketBeat
- Magenta Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/MGTA/price-target/">NASDAQ: MGTA</a>) had its price target lowered by analysts at BTIG Research from $10.00 to $6.00.MarketBeat
- Magenta Therapeutics prioritizes operational spending on MGTA-117 program, cuts workforce [Seeking Alpha]Seeking Alpha
- Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash RunwayBusiness Wire
MGTA
Earnings
- 3/8/22 - Miss
MGTA
Sec Filings
- 5/5/22 - Form SC
- 5/2/22 - Form 8-K
- 5/2/22 - Form DEFA14A
- MGTA's page on the SEC website